nodes	percent_of_prediction	percent_of_DWPC	metapath
Nadolol—ABCB1—Tamoxifen—pancreatic cancer	0.0924	0.199	CbGbCtD
Nadolol—ABCB1—Gemcitabine—pancreatic cancer	0.0796	0.172	CbGbCtD
Nadolol—ABCB1—Erlotinib—pancreatic cancer	0.0785	0.169	CbGbCtD
Nadolol—ABCB1—Irinotecan—pancreatic cancer	0.0709	0.153	CbGbCtD
Nadolol—ABCB1—Docetaxel—pancreatic cancer	0.052	0.112	CbGbCtD
Nadolol—ABCB1—Sunitinib—pancreatic cancer	0.0517	0.112	CbGbCtD
Nadolol—ABCB1—Doxorubicin—pancreatic cancer	0.0388	0.0835	CbGbCtD
Nadolol—Alopecia—Irinotecan—pancreatic cancer	0.001	0.0025	CcSEcCtD
Nadolol—Fluid retention—Epirubicin—pancreatic cancer	0.000998	0.0025	CcSEcCtD
Nadolol—Dry mouth—Sunitinib—pancreatic cancer	0.000996	0.00249	CcSEcCtD
Nadolol—Dyspepsia—Erlotinib—pancreatic cancer	0.000993	0.00249	CcSEcCtD
Nadolol—Decreased appetite—Tamoxifen—pancreatic cancer	0.000991	0.00248	CcSEcCtD
Nadolol—Fatigue—Tamoxifen—pancreatic cancer	0.000983	0.00246	CcSEcCtD
Nadolol—Decreased appetite—Erlotinib—pancreatic cancer	0.00098	0.00245	CcSEcCtD
Nadolol—Oedema—Sunitinib—pancreatic cancer	0.000976	0.00244	CcSEcCtD
Nadolol—Constipation—Tamoxifen—pancreatic cancer	0.000975	0.00244	CcSEcCtD
Nadolol—Pain—Tamoxifen—pancreatic cancer	0.000975	0.00244	CcSEcCtD
Nadolol—Alopecia—Gemcitabine—pancreatic cancer	0.000974	0.00244	CcSEcCtD
Nadolol—Fatigue—Erlotinib—pancreatic cancer	0.000972	0.00243	CcSEcCtD
Nadolol—Flatulence—Irinotecan—pancreatic cancer	0.000971	0.00243	CcSEcCtD
Nadolol—Dry eye—Epirubicin—pancreatic cancer	0.000971	0.00243	CcSEcCtD
Nadolol—Constipation—Erlotinib—pancreatic cancer	0.000964	0.00241	CcSEcCtD
Nadolol—Pain—Erlotinib—pancreatic cancer	0.000964	0.00241	CcSEcCtD
Nadolol—Bronchospasm—Docetaxel—pancreatic cancer	0.000962	0.00241	CcSEcCtD
Nadolol—Shock—Sunitinib—pancreatic cancer	0.000961	0.0024	CcSEcCtD
Nadolol—Alopecia—Fluorouracil—pancreatic cancer	0.000958	0.0024	CcSEcCtD
Nadolol—Pulmonary oedema—Epirubicin—pancreatic cancer	0.000936	0.00234	CcSEcCtD
Nadolol—Anorexia—Sunitinib—pancreatic cancer	0.000931	0.00233	CcSEcCtD
Nadolol—Fluid retention—Doxorubicin—pancreatic cancer	0.000923	0.00231	CcSEcCtD
Nadolol—Dry eye—Doxorubicin—pancreatic cancer	0.000898	0.00225	CcSEcCtD
Nadolol—Body temperature increased—Erlotinib—pancreatic cancer	0.000892	0.00223	CcSEcCtD
Nadolol—Weight increased—Docetaxel—pancreatic cancer	0.00089	0.00223	CcSEcCtD
Nadolol—Vision blurred—Fluorouracil—pancreatic cancer	0.000889	0.00223	CcSEcCtD
Nadolol—Syncope—Irinotecan—pancreatic cancer	0.000884	0.00221	CcSEcCtD
Nadolol—Insomnia—Sunitinib—pancreatic cancer	0.000883	0.00221	CcSEcCtD
Nadolol—Paraesthesia—Sunitinib—pancreatic cancer	0.000877	0.00219	CcSEcCtD
Nadolol—Dyspnoea—Sunitinib—pancreatic cancer	0.00087	0.00218	CcSEcCtD
Nadolol—Loss of consciousness—Irinotecan—pancreatic cancer	0.000866	0.00217	CcSEcCtD
Nadolol—Pulmonary oedema—Doxorubicin—pancreatic cancer	0.000866	0.00217	CcSEcCtD
Nadolol—Cough—Irinotecan—pancreatic cancer	0.00086	0.00215	CcSEcCtD
Nadolol—Dyspepsia—Sunitinib—pancreatic cancer	0.000859	0.00215	CcSEcCtD
Nadolol—Hypertension—Irinotecan—pancreatic cancer	0.000851	0.00213	CcSEcCtD
Nadolol—Decreased appetite—Sunitinib—pancreatic cancer	0.000849	0.00212	CcSEcCtD
Nadolol—Conjunctivitis—Docetaxel—pancreatic cancer	0.000847	0.00212	CcSEcCtD
Nadolol—Fatigue—Sunitinib—pancreatic cancer	0.000842	0.00211	CcSEcCtD
Nadolol—Cardiac failure congestive—Epirubicin—pancreatic cancer	0.000841	0.00211	CcSEcCtD
Nadolol—Cough—Gemcitabine—pancreatic cancer	0.000838	0.0021	CcSEcCtD
Nadolol—Pain—Sunitinib—pancreatic cancer	0.000835	0.00209	CcSEcCtD
Nadolol—Constipation—Sunitinib—pancreatic cancer	0.000835	0.00209	CcSEcCtD
Nadolol—Hypertension—Gemcitabine—pancreatic cancer	0.000829	0.00207	CcSEcCtD
Nadolol—Asthenia—Tamoxifen—pancreatic cancer	0.000818	0.00205	CcSEcCtD
Nadolol—Chest pain—Gemcitabine—pancreatic cancer	0.000817	0.00205	CcSEcCtD
Nadolol—Agranulocytosis—Docetaxel—pancreatic cancer	0.000813	0.00204	CcSEcCtD
Nadolol—Asthenia—Erlotinib—pancreatic cancer	0.000809	0.00203	CcSEcCtD
Nadolol—Pruritus—Tamoxifen—pancreatic cancer	0.000806	0.00202	CcSEcCtD
Nadolol—Oedema—Irinotecan—pancreatic cancer	0.000804	0.00201	CcSEcCtD
Nadolol—Chest pain—Fluorouracil—pancreatic cancer	0.000803	0.00201	CcSEcCtD
Nadolol—Pruritus—Erlotinib—pancreatic cancer	0.000798	0.002	CcSEcCtD
Nadolol—Shock—Irinotecan—pancreatic cancer	0.000791	0.00198	CcSEcCtD
Nadolol—Oedema—Gemcitabine—pancreatic cancer	0.000783	0.00196	CcSEcCtD
Nadolol—Cardiac failure—Epirubicin—pancreatic cancer	0.000782	0.00196	CcSEcCtD
Nadolol—Diarrhoea—Tamoxifen—pancreatic cancer	0.00078	0.00195	CcSEcCtD
Nadolol—Lethargy—Epirubicin—pancreatic cancer	0.000779	0.00195	CcSEcCtD
Nadolol—Cardiac failure congestive—Doxorubicin—pancreatic cancer	0.000778	0.00195	CcSEcCtD
Nadolol—Hyperhidrosis—Irinotecan—pancreatic cancer	0.000777	0.00195	CcSEcCtD
Nadolol—Body temperature increased—Sunitinib—pancreatic cancer	0.000772	0.00193	CcSEcCtD
Nadolol—Diarrhoea—Erlotinib—pancreatic cancer	0.000772	0.00193	CcSEcCtD
Nadolol—Oedema—Fluorouracil—pancreatic cancer	0.00077	0.00193	CcSEcCtD
Nadolol—Anorexia—Irinotecan—pancreatic cancer	0.000767	0.00192	CcSEcCtD
Nadolol—Diplopia—Epirubicin—pancreatic cancer	0.000763	0.00191	CcSEcCtD
Nadolol—Hyperhidrosis—Gemcitabine—pancreatic cancer	0.000757	0.0019	CcSEcCtD
Nadolol—Visual impairment—Docetaxel—pancreatic cancer	0.000754	0.00189	CcSEcCtD
Nadolol—Dizziness—Tamoxifen—pancreatic cancer	0.000754	0.00189	CcSEcCtD
Nadolol—Hypotension—Irinotecan—pancreatic cancer	0.000751	0.00188	CcSEcCtD
Nadolol—Affect lability—Epirubicin—pancreatic cancer	0.000751	0.00188	CcSEcCtD
Nadolol—Anorexia—Gemcitabine—pancreatic cancer	0.000747	0.00187	CcSEcCtD
Nadolol—Dizziness—Erlotinib—pancreatic cancer	0.000746	0.00187	CcSEcCtD
Nadolol—Anorexia—Fluorouracil—pancreatic cancer	0.000734	0.00184	CcSEcCtD
Nadolol—Hypotension—Gemcitabine—pancreatic cancer	0.000732	0.00183	CcSEcCtD
Nadolol—Insomnia—Irinotecan—pancreatic cancer	0.000727	0.00182	CcSEcCtD
Nadolol—Vomiting—Tamoxifen—pancreatic cancer	0.000725	0.00181	CcSEcCtD
Nadolol—Cardiac failure—Doxorubicin—pancreatic cancer	0.000723	0.00181	CcSEcCtD
Nadolol—Mood swings—Epirubicin—pancreatic cancer	0.000723	0.00181	CcSEcCtD
Nadolol—Paraesthesia—Irinotecan—pancreatic cancer	0.000722	0.00181	CcSEcCtD
Nadolol—Lethargy—Doxorubicin—pancreatic cancer	0.00072	0.0018	CcSEcCtD
Nadolol—Hypotension—Fluorouracil—pancreatic cancer	0.00072	0.0018	CcSEcCtD
Nadolol—Rash—Tamoxifen—pancreatic cancer	0.000719	0.0018	CcSEcCtD
Nadolol—Dermatitis—Tamoxifen—pancreatic cancer	0.000718	0.0018	CcSEcCtD
Nadolol—Vomiting—Erlotinib—pancreatic cancer	0.000717	0.0018	CcSEcCtD
Nadolol—Dyspnoea—Irinotecan—pancreatic cancer	0.000717	0.00179	CcSEcCtD
Nadolol—Rash—Erlotinib—pancreatic cancer	0.000711	0.00178	CcSEcCtD
Nadolol—Dermatitis—Erlotinib—pancreatic cancer	0.00071	0.00178	CcSEcCtD
Nadolol—Insomnia—Gemcitabine—pancreatic cancer	0.000709	0.00177	CcSEcCtD
Nadolol—Dyspepsia—Irinotecan—pancreatic cancer	0.000708	0.00177	CcSEcCtD
Nadolol—Diplopia—Doxorubicin—pancreatic cancer	0.000706	0.00177	CcSEcCtD
Nadolol—Paraesthesia—Gemcitabine—pancreatic cancer	0.000703	0.00176	CcSEcCtD
Nadolol—Asthenia—Sunitinib—pancreatic cancer	0.0007	0.00175	CcSEcCtD
Nadolol—Dry skin—Epirubicin—pancreatic cancer	0.000699	0.00175	CcSEcCtD
Nadolol—Decreased appetite—Irinotecan—pancreatic cancer	0.000699	0.00175	CcSEcCtD
Nadolol—Dyspnoea—Gemcitabine—pancreatic cancer	0.000698	0.00175	CcSEcCtD
Nadolol—Insomnia—Fluorouracil—pancreatic cancer	0.000697	0.00174	CcSEcCtD
Nadolol—Affect lability—Doxorubicin—pancreatic cancer	0.000695	0.00174	CcSEcCtD
Nadolol—Fatigue—Irinotecan—pancreatic cancer	0.000693	0.00174	CcSEcCtD
Nadolol—Paraesthesia—Fluorouracil—pancreatic cancer	0.000692	0.00173	CcSEcCtD
Nadolol—Alopecia—Docetaxel—pancreatic cancer	0.000691	0.00173	CcSEcCtD
Nadolol—Pruritus—Sunitinib—pancreatic cancer	0.000691	0.00173	CcSEcCtD
Nadolol—Pain—Irinotecan—pancreatic cancer	0.000688	0.00172	CcSEcCtD
Nadolol—Constipation—Irinotecan—pancreatic cancer	0.000688	0.00172	CcSEcCtD
Nadolol—Dyspnoea—Fluorouracil—pancreatic cancer	0.000687	0.00172	CcSEcCtD
Nadolol—Decreased appetite—Gemcitabine—pancreatic cancer	0.000681	0.0017	CcSEcCtD
Nadolol—Dyspepsia—Fluorouracil—pancreatic cancer	0.000678	0.0017	CcSEcCtD
Nadolol—Nausea—Tamoxifen—pancreatic cancer	0.000677	0.0017	CcSEcCtD
Nadolol—Fatigue—Gemcitabine—pancreatic cancer	0.000675	0.00169	CcSEcCtD
Nadolol—Gastritis—Epirubicin—pancreatic cancer	0.000675	0.00169	CcSEcCtD
Nadolol—Pain—Gemcitabine—pancreatic cancer	0.00067	0.00168	CcSEcCtD
Nadolol—Constipation—Gemcitabine—pancreatic cancer	0.00067	0.00168	CcSEcCtD
Nadolol—Nausea—Erlotinib—pancreatic cancer	0.00067	0.00168	CcSEcCtD
Nadolol—Decreased appetite—Fluorouracil—pancreatic cancer	0.00067	0.00168	CcSEcCtD
Nadolol—Mood swings—Doxorubicin—pancreatic cancer	0.000669	0.00167	CcSEcCtD
Nadolol—Diarrhoea—Sunitinib—pancreatic cancer	0.000668	0.00167	CcSEcCtD
Nadolol—Abdominal distension—Epirubicin—pancreatic cancer	0.000664	0.00166	CcSEcCtD
Nadolol—Pain—Fluorouracil—pancreatic cancer	0.000659	0.00165	CcSEcCtD
Nadolol—Dry skin—Doxorubicin—pancreatic cancer	0.000647	0.00162	CcSEcCtD
Nadolol—Dizziness—Sunitinib—pancreatic cancer	0.000646	0.00162	CcSEcCtD
Nadolol—Body temperature increased—Irinotecan—pancreatic cancer	0.000636	0.00159	CcSEcCtD
Nadolol—Gastritis—Doxorubicin—pancreatic cancer	0.000625	0.00156	CcSEcCtD
Nadolol—Vomiting—Sunitinib—pancreatic cancer	0.000621	0.00155	CcSEcCtD
Nadolol—Body temperature increased—Gemcitabine—pancreatic cancer	0.000619	0.00155	CcSEcCtD
Nadolol—Rash—Sunitinib—pancreatic cancer	0.000616	0.00154	CcSEcCtD
Nadolol—Dermatitis—Sunitinib—pancreatic cancer	0.000615	0.00154	CcSEcCtD
Nadolol—Abdominal distension—Doxorubicin—pancreatic cancer	0.000614	0.00154	CcSEcCtD
Nadolol—Syncope—Docetaxel—pancreatic cancer	0.000611	0.00153	CcSEcCtD
Nadolol—Body temperature increased—Fluorouracil—pancreatic cancer	0.000609	0.00152	CcSEcCtD
Nadolol—Weight increased—Epirubicin—pancreatic cancer	0.0006	0.0015	CcSEcCtD
Nadolol—Loss of consciousness—Docetaxel—pancreatic cancer	0.000599	0.0015	CcSEcCtD
Nadolol—Cough—Docetaxel—pancreatic cancer	0.000594	0.00149	CcSEcCtD
Nadolol—Hypertension—Docetaxel—pancreatic cancer	0.000588	0.00147	CcSEcCtD
Nadolol—Chest pain—Docetaxel—pancreatic cancer	0.00058	0.00145	CcSEcCtD
Nadolol—Nausea—Sunitinib—pancreatic cancer	0.00058	0.00145	CcSEcCtD
Nadolol—Asthenia—Irinotecan—pancreatic cancer	0.000577	0.00144	CcSEcCtD
Nadolol—Conjunctivitis—Epirubicin—pancreatic cancer	0.000571	0.00143	CcSEcCtD
Nadolol—Dry mouth—Docetaxel—pancreatic cancer	0.000567	0.00142	CcSEcCtD
Nadolol—Sweating—Epirubicin—pancreatic cancer	0.000564	0.00141	CcSEcCtD
Nadolol—Asthenia—Gemcitabine—pancreatic cancer	0.000562	0.00141	CcSEcCtD
Nadolol—Oedema—Docetaxel—pancreatic cancer	0.000556	0.00139	CcSEcCtD
Nadolol—Weight increased—Doxorubicin—pancreatic cancer	0.000555	0.00139	CcSEcCtD
Nadolol—Pruritus—Gemcitabine—pancreatic cancer	0.000554	0.00139	CcSEcCtD
Nadolol—Diarrhoea—Irinotecan—pancreatic cancer	0.00055	0.00138	CcSEcCtD
Nadolol—Agranulocytosis—Epirubicin—pancreatic cancer	0.000549	0.00137	CcSEcCtD
Nadolol—Shock—Docetaxel—pancreatic cancer	0.000547	0.00137	CcSEcCtD
Nadolol—Pruritus—Fluorouracil—pancreatic cancer	0.000545	0.00136	CcSEcCtD
Nadolol—Bradycardia—Epirubicin—pancreatic cancer	0.000537	0.00135	CcSEcCtD
Nadolol—Diarrhoea—Gemcitabine—pancreatic cancer	0.000536	0.00134	CcSEcCtD
Nadolol—Dizziness—Irinotecan—pancreatic cancer	0.000532	0.00133	CcSEcCtD
Nadolol—Anorexia—Docetaxel—pancreatic cancer	0.00053	0.00133	CcSEcCtD
Nadolol—Conjunctivitis—Doxorubicin—pancreatic cancer	0.000529	0.00132	CcSEcCtD
Nadolol—Diarrhoea—Fluorouracil—pancreatic cancer	0.000527	0.00132	CcSEcCtD
Nadolol—Sweating—Doxorubicin—pancreatic cancer	0.000522	0.00131	CcSEcCtD
Nadolol—Hypotension—Docetaxel—pancreatic cancer	0.000519	0.0013	CcSEcCtD
Nadolol—Vomiting—Irinotecan—pancreatic cancer	0.000511	0.00128	CcSEcCtD
Nadolol—Dizziness—Fluorouracil—pancreatic cancer	0.000509	0.00128	CcSEcCtD
Nadolol—Visual impairment—Epirubicin—pancreatic cancer	0.000509	0.00127	CcSEcCtD
Nadolol—Agranulocytosis—Doxorubicin—pancreatic cancer	0.000508	0.00127	CcSEcCtD
Nadolol—Rash—Irinotecan—pancreatic cancer	0.000507	0.00127	CcSEcCtD
Nadolol—Dermatitis—Irinotecan—pancreatic cancer	0.000507	0.00127	CcSEcCtD
Nadolol—Insomnia—Docetaxel—pancreatic cancer	0.000503	0.00126	CcSEcCtD
Nadolol—Paraesthesia—Docetaxel—pancreatic cancer	0.000499	0.00125	CcSEcCtD
Nadolol—Vomiting—Gemcitabine—pancreatic cancer	0.000498	0.00125	CcSEcCtD
Nadolol—Bradycardia—Doxorubicin—pancreatic cancer	0.000497	0.00124	CcSEcCtD
Nadolol—Dyspnoea—Docetaxel—pancreatic cancer	0.000496	0.00124	CcSEcCtD
Nadolol—Rash—Gemcitabine—pancreatic cancer	0.000494	0.00124	CcSEcCtD
Nadolol—Dermatitis—Gemcitabine—pancreatic cancer	0.000493	0.00124	CcSEcCtD
Nadolol—Tinnitus—Epirubicin—pancreatic cancer	0.000492	0.00123	CcSEcCtD
Nadolol—Vomiting—Fluorouracil—pancreatic cancer	0.00049	0.00123	CcSEcCtD
Nadolol—Dyspepsia—Docetaxel—pancreatic cancer	0.000489	0.00123	CcSEcCtD
Nadolol—Rash—Fluorouracil—pancreatic cancer	0.000486	0.00122	CcSEcCtD
Nadolol—Dermatitis—Fluorouracil—pancreatic cancer	0.000485	0.00121	CcSEcCtD
Nadolol—Decreased appetite—Docetaxel—pancreatic cancer	0.000483	0.00121	CcSEcCtD
Nadolol—Fatigue—Docetaxel—pancreatic cancer	0.000479	0.0012	CcSEcCtD
Nadolol—Nausea—Irinotecan—pancreatic cancer	0.000478	0.0012	CcSEcCtD
Nadolol—Pain—Docetaxel—pancreatic cancer	0.000475	0.00119	CcSEcCtD
Nadolol—Constipation—Docetaxel—pancreatic cancer	0.000475	0.00119	CcSEcCtD
Nadolol—Visual impairment—Doxorubicin—pancreatic cancer	0.000471	0.00118	CcSEcCtD
Nadolol—Alopecia—Epirubicin—pancreatic cancer	0.000466	0.00117	CcSEcCtD
Nadolol—Nausea—Gemcitabine—pancreatic cancer	0.000465	0.00116	CcSEcCtD
Nadolol—Nausea—Fluorouracil—pancreatic cancer	0.000458	0.00115	CcSEcCtD
Nadolol—Tinnitus—Doxorubicin—pancreatic cancer	0.000455	0.00114	CcSEcCtD
Nadolol—Flatulence—Epirubicin—pancreatic cancer	0.000453	0.00113	CcSEcCtD
Nadolol—Body temperature increased—Docetaxel—pancreatic cancer	0.000439	0.0011	CcSEcCtD
Nadolol—Vision blurred—Epirubicin—pancreatic cancer	0.000433	0.00108	CcSEcCtD
Nadolol—Alopecia—Doxorubicin—pancreatic cancer	0.000432	0.00108	CcSEcCtD
Nadolol—Flatulence—Doxorubicin—pancreatic cancer	0.000419	0.00105	CcSEcCtD
Nadolol—Syncope—Epirubicin—pancreatic cancer	0.000412	0.00103	CcSEcCtD
Nadolol—Loss of consciousness—Epirubicin—pancreatic cancer	0.000404	0.00101	CcSEcCtD
Nadolol—Cough—Epirubicin—pancreatic cancer	0.000401	0.001	CcSEcCtD
Nadolol—Vision blurred—Doxorubicin—pancreatic cancer	0.000401	0.001	CcSEcCtD
Nadolol—Asthenia—Docetaxel—pancreatic cancer	0.000399	0.000999	CcSEcCtD
Nadolol—Hypertension—Epirubicin—pancreatic cancer	0.000397	0.000993	CcSEcCtD
Nadolol—Pruritus—Docetaxel—pancreatic cancer	0.000393	0.000985	CcSEcCtD
Nadolol—Chest pain—Epirubicin—pancreatic cancer	0.000391	0.000979	CcSEcCtD
Nadolol—Dry mouth—Epirubicin—pancreatic cancer	0.000383	0.000958	CcSEcCtD
Nadolol—Syncope—Doxorubicin—pancreatic cancer	0.000381	0.000954	CcSEcCtD
Nadolol—Diarrhoea—Docetaxel—pancreatic cancer	0.00038	0.000952	CcSEcCtD
Nadolol—Oedema—Epirubicin—pancreatic cancer	0.000375	0.000939	CcSEcCtD
Nadolol—Loss of consciousness—Doxorubicin—pancreatic cancer	0.000374	0.000935	CcSEcCtD
Nadolol—Cough—Doxorubicin—pancreatic cancer	0.000371	0.000929	CcSEcCtD
Nadolol—Shock—Epirubicin—pancreatic cancer	0.000369	0.000924	CcSEcCtD
Nadolol—Dizziness—Docetaxel—pancreatic cancer	0.000368	0.00092	CcSEcCtD
Nadolol—Hypertension—Doxorubicin—pancreatic cancer	0.000367	0.000919	CcSEcCtD
Nadolol—Hyperhidrosis—Epirubicin—pancreatic cancer	0.000362	0.000907	CcSEcCtD
Nadolol—Chest pain—Doxorubicin—pancreatic cancer	0.000362	0.000906	CcSEcCtD
Nadolol—Anorexia—Epirubicin—pancreatic cancer	0.000357	0.000895	CcSEcCtD
Nadolol—Dry mouth—Doxorubicin—pancreatic cancer	0.000354	0.000886	CcSEcCtD
Nadolol—Vomiting—Docetaxel—pancreatic cancer	0.000353	0.000885	CcSEcCtD
Nadolol—Rash—Docetaxel—pancreatic cancer	0.000351	0.000878	CcSEcCtD
Nadolol—Hypotension—Epirubicin—pancreatic cancer	0.00035	0.000877	CcSEcCtD
Nadolol—Dermatitis—Docetaxel—pancreatic cancer	0.00035	0.000877	CcSEcCtD
Nadolol—Oedema—Doxorubicin—pancreatic cancer	0.000347	0.000869	CcSEcCtD
Nadolol—Shock—Doxorubicin—pancreatic cancer	0.000341	0.000855	CcSEcCtD
Nadolol—Insomnia—Epirubicin—pancreatic cancer	0.000339	0.000849	CcSEcCtD
Nadolol—Paraesthesia—Epirubicin—pancreatic cancer	0.000337	0.000843	CcSEcCtD
Nadolol—Hyperhidrosis—Doxorubicin—pancreatic cancer	0.000335	0.00084	CcSEcCtD
Nadolol—Dyspnoea—Epirubicin—pancreatic cancer	0.000334	0.000837	CcSEcCtD
Nadolol—Anorexia—Doxorubicin—pancreatic cancer	0.000331	0.000828	CcSEcCtD
Nadolol—Nausea—Docetaxel—pancreatic cancer	0.00033	0.000827	CcSEcCtD
Nadolol—Dyspepsia—Epirubicin—pancreatic cancer	0.00033	0.000826	CcSEcCtD
Nadolol—Decreased appetite—Epirubicin—pancreatic cancer	0.000326	0.000816	CcSEcCtD
Nadolol—Hypotension—Doxorubicin—pancreatic cancer	0.000324	0.000812	CcSEcCtD
Nadolol—Fatigue—Epirubicin—pancreatic cancer	0.000323	0.000809	CcSEcCtD
Nadolol—Pain—Epirubicin—pancreatic cancer	0.000321	0.000803	CcSEcCtD
Nadolol—Constipation—Epirubicin—pancreatic cancer	0.000321	0.000803	CcSEcCtD
Nadolol—Insomnia—Doxorubicin—pancreatic cancer	0.000314	0.000786	CcSEcCtD
Nadolol—Paraesthesia—Doxorubicin—pancreatic cancer	0.000312	0.00078	CcSEcCtD
Nadolol—Dyspnoea—Doxorubicin—pancreatic cancer	0.000309	0.000774	CcSEcCtD
Nadolol—Dyspepsia—Doxorubicin—pancreatic cancer	0.000305	0.000765	CcSEcCtD
Nadolol—Decreased appetite—Doxorubicin—pancreatic cancer	0.000302	0.000755	CcSEcCtD
Nadolol—Fatigue—Doxorubicin—pancreatic cancer	0.000299	0.000749	CcSEcCtD
Nadolol—Pain—Doxorubicin—pancreatic cancer	0.000297	0.000743	CcSEcCtD
Nadolol—Constipation—Doxorubicin—pancreatic cancer	0.000297	0.000743	CcSEcCtD
Nadolol—Body temperature increased—Epirubicin—pancreatic cancer	0.000296	0.000742	CcSEcCtD
Nadolol—Body temperature increased—Doxorubicin—pancreatic cancer	0.000274	0.000687	CcSEcCtD
Nadolol—Asthenia—Epirubicin—pancreatic cancer	0.000269	0.000674	CcSEcCtD
Nadolol—Pruritus—Epirubicin—pancreatic cancer	0.000265	0.000664	CcSEcCtD
Nadolol—Diarrhoea—Epirubicin—pancreatic cancer	0.000257	0.000642	CcSEcCtD
Nadolol—Asthenia—Doxorubicin—pancreatic cancer	0.000249	0.000623	CcSEcCtD
Nadolol—Dizziness—Epirubicin—pancreatic cancer	0.000248	0.000621	CcSEcCtD
Nadolol—Pruritus—Doxorubicin—pancreatic cancer	0.000245	0.000615	CcSEcCtD
Nadolol—Vomiting—Epirubicin—pancreatic cancer	0.000238	0.000597	CcSEcCtD
Nadolol—Diarrhoea—Doxorubicin—pancreatic cancer	0.000237	0.000594	CcSEcCtD
Nadolol—Rash—Epirubicin—pancreatic cancer	0.000236	0.000592	CcSEcCtD
Nadolol—Dermatitis—Epirubicin—pancreatic cancer	0.000236	0.000591	CcSEcCtD
Nadolol—Dizziness—Doxorubicin—pancreatic cancer	0.000229	0.000574	CcSEcCtD
Nadolol—Nausea—Epirubicin—pancreatic cancer	0.000223	0.000558	CcSEcCtD
Nadolol—Vomiting—Doxorubicin—pancreatic cancer	0.000221	0.000552	CcSEcCtD
Nadolol—Rash—Doxorubicin—pancreatic cancer	0.000219	0.000548	CcSEcCtD
Nadolol—Dermatitis—Doxorubicin—pancreatic cancer	0.000219	0.000547	CcSEcCtD
Nadolol—Nausea—Doxorubicin—pancreatic cancer	0.000206	0.000516	CcSEcCtD
Nadolol—ADRB3—GPCR downstream signaling—PIK3CG—pancreatic cancer	0.000114	0.000838	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—GCG—pancreatic cancer	0.000114	0.000838	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CCKBR—pancreatic cancer	0.000114	0.000837	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—SST—pancreatic cancer	0.000114	0.000835	CbGpPWpGaD
Nadolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL8—pancreatic cancer	0.000114	0.000833	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—JAG1—pancreatic cancer	0.000114	0.000832	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—NOTCH3—pancreatic cancer	0.000113	0.000828	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—GCG—pancreatic cancer	0.000112	0.00082	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—DTX4—pancreatic cancer	0.00011	0.000805	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—GLI1—pancreatic cancer	0.00011	0.000805	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	0.00011	0.000804	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—AGTR1—pancreatic cancer	0.000109	0.000799	CbGpPWpGaD
Nadolol—ABCB1—HIF-1-alpha transcription factor network—AKT1—pancreatic cancer	0.000109	0.000797	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—CNR1—pancreatic cancer	0.000108	0.000788	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—DTX4—pancreatic cancer	0.000107	0.000787	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—GLI1—pancreatic cancer	0.000107	0.000787	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CNR1—pancreatic cancer	0.000107	0.000784	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PPP2R5B—pancreatic cancer	0.000107	0.000783	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—NRP1—pancreatic cancer	0.000107	0.000783	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—AGTR1—pancreatic cancer	0.000107	0.000782	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—CNR1—pancreatic cancer	0.000105	0.000771	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—NRP1—pancreatic cancer	0.000105	0.000766	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PPP2R5B—pancreatic cancer	0.000105	0.000766	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—PIK3CG—pancreatic cancer	0.000104	0.000761	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—GCG—pancreatic cancer	0.000104	0.000761	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—GCG—pancreatic cancer	0.000103	0.000757	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—HEY2—pancreatic cancer	0.000103	0.000753	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—GCG—pancreatic cancer	0.000102	0.000744	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—HEY2—pancreatic cancer	0.000101	0.000737	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—PIK3CD—pancreatic cancer	0.000101	0.000737	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—GAST—pancreatic cancer	0.000101	0.000736	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—AGTR1—pancreatic cancer	9.91e-05	0.000726	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—AGTR1—pancreatic cancer	9.87e-05	0.000723	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—GAST—pancreatic cancer	9.83e-05	0.00072	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—STK11—pancreatic cancer	9.73e-05	0.000712	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—AGTR1—pancreatic cancer	9.7e-05	0.00071	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—SCT—pancreatic cancer	9.53e-05	0.000698	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—HEY1—pancreatic cancer	9.53e-05	0.000698	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—SCT—pancreatic cancer	9.32e-05	0.000682	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—HEY1—pancreatic cancer	9.32e-05	0.000682	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—pancreatic cancer	9.25e-05	0.000677	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—PIK3CD—pancreatic cancer	9.14e-05	0.000669	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CCK—pancreatic cancer	9.09e-05	0.000666	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PRSS1—pancreatic cancer	9.01e-05	0.00066	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CCK—pancreatic cancer	8.89e-05	0.000651	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CNR2—pancreatic cancer	8.86e-05	0.000649	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—GLP1R—pancreatic cancer	8.86e-05	0.000649	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—CXCL8—pancreatic cancer	8.85e-05	0.000648	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—PIK3CB—pancreatic cancer	8.77e-05	0.000642	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CCKAR—pancreatic cancer	8.71e-05	0.000638	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CNR2—pancreatic cancer	8.66e-05	0.000634	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—GLP1R—pancreatic cancer	8.66e-05	0.000634	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—CXCL8—pancreatic cancer	8.66e-05	0.000634	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—pancreatic cancer	8.59e-05	0.000629	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CCKAR—pancreatic cancer	8.52e-05	0.000624	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—SMAD4—pancreatic cancer	8.52e-05	0.000624	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—JAG2—pancreatic cancer	8.45e-05	0.000619	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—CXCL8—pancreatic cancer	8.43e-05	0.000617	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—pancreatic cancer	8.36e-05	0.000612	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MEN1—pancreatic cancer	8.33e-05	0.00061	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—HES1—pancreatic cancer	8.32e-05	0.000609	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—pancreatic cancer	8.28e-05	0.000606	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—JAG2—pancreatic cancer	8.27e-05	0.000605	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MEN1—pancreatic cancer	8.15e-05	0.000597	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—pancreatic cancer	8.07e-05	0.000591	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—PIK3CB—pancreatic cancer	7.96e-05	0.000583	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—SHH—pancreatic cancer	7.94e-05	0.000582	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—NOTCH4—pancreatic cancer	7.89e-05	0.000578	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IAPP—pancreatic cancer	7.85e-05	0.000575	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ARG2—pancreatic cancer	7.82e-05	0.000572	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—SHH—pancreatic cancer	7.77e-05	0.000569	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—NOTCH4—pancreatic cancer	7.72e-05	0.000565	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IAPP—pancreatic cancer	7.68e-05	0.000562	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—CXCL8—pancreatic cancer	7.65e-05	0.00056	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PTHLH—pancreatic cancer	7.53e-05	0.000551	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PTCH1—pancreatic cancer	7.53e-05	0.000551	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—pancreatic cancer	7.48e-05	0.000548	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PTHLH—pancreatic cancer	7.37e-05	0.000539	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PTCH1—pancreatic cancer	7.37e-05	0.000539	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—TERT—pancreatic cancer	7.29e-05	0.000534	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—pancreatic cancer	7.29e-05	0.000534	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—HIF1A—pancreatic cancer	6.97e-05	0.00051	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—TSC2—pancreatic cancer	6.95e-05	0.000509	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—SST—pancreatic cancer	6.89e-05	0.000504	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—TYMP—pancreatic cancer	6.83e-05	0.0005	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—APOE—pancreatic cancer	6.8e-05	0.000498	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—PIK3CG—pancreatic cancer	6.79e-05	0.000497	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—JAG1—pancreatic cancer	6.74e-05	0.000494	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—SST—pancreatic cancer	6.74e-05	0.000493	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—NOTCH3—pancreatic cancer	6.71e-05	0.000492	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—pancreatic cancer	6.7e-05	0.000491	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—pancreatic cancer	6.69e-05	0.00049	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—KDR—pancreatic cancer	6.67e-05	0.000488	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—PIK3CG—pancreatic cancer	6.65e-05	0.000487	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—JAG1—pancreatic cancer	6.59e-05	0.000483	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—NOTCH3—pancreatic cancer	6.57e-05	0.000481	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—pancreatic cancer	6.56e-05	0.00048	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CNR1—pancreatic cancer	6.36e-05	0.000465	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—NFKBIA—pancreatic cancer	6.34e-05	0.000464	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—NOTCH1—pancreatic cancer	6.28e-05	0.00046	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—pancreatic cancer	6.25e-05	0.000457	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CNR1—pancreatic cancer	6.22e-05	0.000455	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—pancreatic cancer	6.19e-05	0.000454	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—PIK3CG—pancreatic cancer	6.17e-05	0.000452	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PIK3CG—pancreatic cancer	6.14e-05	0.00045	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—NRAS—pancreatic cancer	6.14e-05	0.00045	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—GCG—pancreatic cancer	6.14e-05	0.00045	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—EGF—pancreatic cancer	6.07e-05	0.000444	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—PIK3CG—pancreatic cancer	6.04e-05	0.000442	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—GCG—pancreatic cancer	6.01e-05	0.00044	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—PIK3CD—pancreatic cancer	5.97e-05	0.000437	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—AGTR1—pancreatic cancer	5.86e-05	0.000429	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—PIK3CD—pancreatic cancer	5.84e-05	0.000428	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—STK11—pancreatic cancer	5.77e-05	0.000423	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—AGTR1—pancreatic cancer	5.73e-05	0.00042	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—pancreatic cancer	5.69e-05	0.000417	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—STK11—pancreatic cancer	5.65e-05	0.000413	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—EGFR—pancreatic cancer	5.59e-05	0.00041	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GLP1R—pancreatic cancer	5.51e-05	0.000403	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—pancreatic cancer	5.51e-05	0.000403	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—PIK3CD—pancreatic cancer	5.42e-05	0.000397	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—DPYD—pancreatic cancer	5.42e-05	0.000397	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PIK3CD—pancreatic cancer	5.4e-05	0.000395	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—PIK3CA—pancreatic cancer	5.35e-05	0.000391	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—PIK3CD—pancreatic cancer	5.31e-05	0.000388	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—KRAS—pancreatic cancer	5.28e-05	0.000387	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—PIK3CB—pancreatic cancer	5.21e-05	0.000381	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—SLC2A2—pancreatic cancer	5.14e-05	0.000376	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—PIK3CB—pancreatic cancer	5.09e-05	0.000373	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—SMAD4—pancreatic cancer	5.06e-05	0.00037	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—CXCL8—pancreatic cancer	5e-05	0.000366	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—SMAD4—pancreatic cancer	4.95e-05	0.000362	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—HES1—pancreatic cancer	4.94e-05	0.000361	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—CXCL8—pancreatic cancer	4.89e-05	0.000358	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—PIK3CA—pancreatic cancer	4.86e-05	0.000356	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—HES1—pancreatic cancer	4.83e-05	0.000354	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—PIK3CB—pancreatic cancer	4.73e-05	0.000346	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PIK3CB—pancreatic cancer	4.71e-05	0.000345	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—pancreatic cancer	4.65e-05	0.00034	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—PIK3CB—pancreatic cancer	4.62e-05	0.000339	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—CXCL8—pancreatic cancer	4.54e-05	0.000333	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CXCL8—pancreatic cancer	4.52e-05	0.000331	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—HRAS—pancreatic cancer	4.49e-05	0.000329	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—CXCL8—pancreatic cancer	4.44e-05	0.000325	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—AKT1—pancreatic cancer	4.37e-05	0.00032	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CASP3—pancreatic cancer	4.33e-05	0.000317	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—TERT—pancreatic cancer	4.33e-05	0.000317	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—TERT—pancreatic cancer	4.23e-05	0.00031	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CCND1—pancreatic cancer	4.21e-05	0.000308	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CTNNB1—pancreatic cancer	4.17e-05	0.000305	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—HIF1A—pancreatic cancer	4.14e-05	0.000303	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—TSC2—pancreatic cancer	4.13e-05	0.000302	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MMP9—pancreatic cancer	4.09e-05	0.000299	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PTEN—pancreatic cancer	4.07e-05	0.000298	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—HIF1A—pancreatic cancer	4.05e-05	0.000296	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—APOE—pancreatic cancer	4.04e-05	0.000296	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—TSC2—pancreatic cancer	4.04e-05	0.000296	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CD44—pancreatic cancer	3.98e-05	0.000292	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—AKT1—pancreatic cancer	3.97e-05	0.00029	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—KDR—pancreatic cancer	3.96e-05	0.00029	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—APOE—pancreatic cancer	3.95e-05	0.000289	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—KDR—pancreatic cancer	3.87e-05	0.000283	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GCG—pancreatic cancer	3.82e-05	0.000279	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—SRC—pancreatic cancer	3.77e-05	0.000276	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—NFKBIA—pancreatic cancer	3.76e-05	0.000276	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—NOTCH1—pancreatic cancer	3.73e-05	0.000273	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—NFKBIA—pancreatic cancer	3.68e-05	0.00027	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—VEGFA—pancreatic cancer	3.67e-05	0.000269	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—NOTCH1—pancreatic cancer	3.65e-05	0.000267	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PIK3CG—pancreatic cancer	3.64e-05	0.000267	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—NRAS—pancreatic cancer	3.64e-05	0.000267	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—STAT3—pancreatic cancer	3.64e-05	0.000266	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—NRAS—pancreatic cancer	3.63e-05	0.000266	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—EGF—pancreatic cancer	3.6e-05	0.000264	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—STK11—pancreatic cancer	3.59e-05	0.000263	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PIK3CG—pancreatic cancer	3.57e-05	0.000261	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—NRAS—pancreatic cancer	3.57e-05	0.000261	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—EGF—pancreatic cancer	3.52e-05	0.000258	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MYC—pancreatic cancer	3.38e-05	0.000247	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—TGFB1—pancreatic cancer	3.37e-05	0.000247	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—EGFR—pancreatic cancer	3.32e-05	0.000243	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—EGFR—pancreatic cancer	3.3e-05	0.000242	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—EGFR—pancreatic cancer	3.25e-05	0.000238	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PIK3CD—pancreatic cancer	3.2e-05	0.000235	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—PIK3CA—pancreatic cancer	3.17e-05	0.000232	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—KRAS—pancreatic cancer	3.14e-05	0.00023	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PIK3CD—pancreatic cancer	3.13e-05	0.000229	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—KRAS—pancreatic cancer	3.12e-05	0.000229	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—PIK3CA—pancreatic cancer	3.1e-05	0.000227	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—TYMS—pancreatic cancer	3.09e-05	0.000226	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—KRAS—pancreatic cancer	3.07e-05	0.000225	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—PIK3CA—pancreatic cancer	2.88e-05	0.000211	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PIK3CA—pancreatic cancer	2.87e-05	0.00021	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—PIK3CA—pancreatic cancer	2.82e-05	0.000206	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PIK3CB—pancreatic cancer	2.79e-05	0.000204	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—TP53—pancreatic cancer	2.77e-05	0.000203	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PIK3CB—pancreatic cancer	2.73e-05	0.0002	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CXCL8—pancreatic cancer	2.68e-05	0.000197	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—HRAS—pancreatic cancer	2.67e-05	0.000195	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—HRAS—pancreatic cancer	2.65e-05	0.000194	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CXCL8—pancreatic cancer	2.63e-05	0.000192	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—HRAS—pancreatic cancer	2.61e-05	0.000191	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—AKT1—pancreatic cancer	2.59e-05	0.00019	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CASP3—pancreatic cancer	2.57e-05	0.000188	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—AKT1—pancreatic cancer	2.54e-05	0.000186	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CASP3—pancreatic cancer	2.51e-05	0.000184	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—APOE—pancreatic cancer	2.51e-05	0.000184	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CCND1—pancreatic cancer	2.5e-05	0.000183	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CTNNB1—pancreatic cancer	2.48e-05	0.000181	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CCND1—pancreatic cancer	2.45e-05	0.000179	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MMP9—pancreatic cancer	2.43e-05	0.000178	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CTNNB1—pancreatic cancer	2.42e-05	0.000177	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PTEN—pancreatic cancer	2.41e-05	0.000177	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MMP9—pancreatic cancer	2.37e-05	0.000174	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PTEN—pancreatic cancer	2.36e-05	0.000173	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—AKT1—pancreatic cancer	2.35e-05	0.000172	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—AKT1—pancreatic cancer	2.34e-05	0.000172	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—AKT1—pancreatic cancer	2.3e-05	0.000169	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PIK3CG—pancreatic cancer	2.27e-05	0.000166	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—SRC—pancreatic cancer	2.24e-05	0.000164	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—SRC—pancreatic cancer	2.19e-05	0.00016	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PPARG—pancreatic cancer	2.19e-05	0.00016	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—VEGFA—pancreatic cancer	2.18e-05	0.00016	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—STAT3—pancreatic cancer	2.16e-05	0.000158	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—NRAS—pancreatic cancer	2.15e-05	0.000158	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—VEGFA—pancreatic cancer	2.13e-05	0.000156	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—STAT3—pancreatic cancer	2.11e-05	0.000155	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—NRAS—pancreatic cancer	2.11e-05	0.000154	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MYC—pancreatic cancer	2.01e-05	0.000147	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—TGFB1—pancreatic cancer	2e-05	0.000146	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PIK3CD—pancreatic cancer	1.99e-05	0.000146	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MYC—pancreatic cancer	1.96e-05	0.000144	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—EGFR—pancreatic cancer	1.96e-05	0.000144	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—TGFB1—pancreatic cancer	1.96e-05	0.000143	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—EGFR—pancreatic cancer	1.92e-05	0.00014	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—KRAS—pancreatic cancer	1.85e-05	0.000136	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—KRAS—pancreatic cancer	1.81e-05	0.000133	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PIK3CB—pancreatic cancer	1.74e-05	0.000127	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PTGS2—pancreatic cancer	1.72e-05	0.000126	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PIK3CA—pancreatic cancer	1.7e-05	0.000125	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PIK3CA—pancreatic cancer	1.67e-05	0.000122	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—TP53—pancreatic cancer	1.65e-05	0.000121	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—TP53—pancreatic cancer	1.61e-05	0.000118	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—HRAS—pancreatic cancer	1.58e-05	0.000115	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—HRAS—pancreatic cancer	1.54e-05	0.000113	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PTEN—pancreatic cancer	1.5e-05	0.00011	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—AKT1—pancreatic cancer	1.39e-05	0.000102	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—AKT1—pancreatic cancer	1.36e-05	9.96e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PIK3CA—pancreatic cancer	1.06e-05	7.75e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—AKT1—pancreatic cancer	8.65e-06	6.33e-05	CbGpPWpGaD
